Danelle F. James

14.8k total citations · 2 hit papers
101 papers, 3.9k citations indexed

About

Danelle F. James is a scholar working on Genetics, Pathology and Forensic Medicine and Immunology. According to data from OpenAlex, Danelle F. James has authored 101 papers receiving a total of 3.9k indexed citations (citations by other indexed papers that have themselves been cited), including 94 papers in Genetics, 54 papers in Pathology and Forensic Medicine and 33 papers in Immunology. Recurrent topics in Danelle F. James's work include Chronic Lymphocytic Leukemia Research (94 papers), Lymphoma Diagnosis and Treatment (53 papers) and Immunodeficiency and Autoimmune Disorders (31 papers). Danelle F. James is often cited by papers focused on Chronic Lymphocytic Leukemia Research (94 papers), Lymphoma Diagnosis and Treatment (53 papers) and Immunodeficiency and Autoimmune Disorders (31 papers). Danelle F. James collaborates with scholars based in United States, United Kingdom and Italy. Danelle F. James's co-authors include Jan A. Burger, William G. Wierda, Thomas J. Kipps, Susan O’Brien, John C. Byrd, Steven Coutré, Richard R. Furman, Ian W. Flinn, Jeffrey A. Jones and Amy J. Johnson and has published in prestigious journals such as Proceedings of the National Academy of Sciences, Journal of Clinical Oncology and Blood.

In The Last Decade

Danelle F. James

98 papers receiving 3.9k citations

Hit Papers

Three-year follow-up of t... 2015 2026 2018 2022 2015 2018 100 200 300 400
What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

  1. Three-year follow-up of treatment-naïve and previously treated patients with CLL and SLL receiving single-agent ibrutinib
    2015 484 citations John C. Byrd, Richard R. Furman et al. Blood profile →
  2. Ibrutinib plus obinutuzumab versus chlorambucil plus obinutuzumab in first-line treatment of chronic lymphocytic leukaemia (iLLUMINATE): a multicentre, randomised, open-label, phase 3 trial
    2018 380 citations Carol Moreno, Richard Greil et al. The Lancet Oncology profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Danelle F. James United States 31 3.0k 2.4k 1.5k 1.2k 620 101 3.9k
Carolyn Owen Canada 21 2.1k 0.7× 1.8k 0.7× 782 0.5× 989 0.9× 702 1.1× 99 3.1k
Francesca Romana Mauro Italy 31 2.4k 0.8× 1.7k 0.7× 1.3k 0.9× 739 0.6× 630 1.0× 157 3.3k
Preetesh Jain United States 32 2.2k 0.7× 1.5k 0.6× 846 0.6× 1.4k 1.2× 1.0k 1.6× 181 3.7k
Marı́a Rozman Spain 30 2.1k 0.7× 1.6k 0.7× 910 0.6× 1.4k 1.2× 631 1.0× 128 3.6k
Jacqueline C. Barrientos United States 27 2.3k 0.8× 1.9k 0.8× 995 0.7× 672 0.6× 630 1.0× 178 2.9k
Jeffrey Matous United States 29 1.6k 0.5× 2.3k 1.0× 831 0.6× 1.2k 1.1× 1.8k 3.0× 128 4.2k
Leslie A. Andritsos United States 30 2.1k 0.7× 1.5k 0.6× 1.1k 0.7× 866 0.7× 1.0k 1.6× 161 3.5k
Wei Ding United States 25 1.7k 0.6× 1.2k 0.5× 751 0.5× 479 0.4× 411 0.7× 117 2.2k
E Montserrat Spain 30 1.4k 0.5× 1.8k 0.7× 820 0.6× 769 0.7× 1.0k 1.7× 97 3.0k
KR Rai United States 11 3.9k 1.3× 2.9k 1.2× 2.1k 1.4× 689 0.6× 492 0.8× 24 4.2k

Countries citing papers authored by Danelle F. James

Since Specialization
Citations

This map shows the geographic impact of Danelle F. James's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Danelle F. James with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Danelle F. James more than expected).

Fields of papers citing papers by Danelle F. James

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Danelle F. James. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Danelle F. James. The network helps show where Danelle F. James may publish in the future.

Co-authorship network of co-authors of Danelle F. James

This figure shows the co-authorship network connecting the top 25 collaborators of Danelle F. James. A scholar is included among the top collaborators of Danelle F. James based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Danelle F. James. Danelle F. James is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Woyach, Jennifer A., Paolo Ghia, John C. Byrd, et al.. (2023). B-cell Receptor Pathway Mutations Are Infrequent in Patients with Chronic Lymphocytic Leukemia on Continuous Ibrutinib Therapy. Clinical Cancer Research. 29(16). 3065–3073. 7 indexed citations
2.
Okhuysen, Pablo C., Mayur Ramesh, Kevin W. Garey, et al.. (2022). 730. A Phase 3, Randomized, Double-Blind Study to Evaluate the Efficacy and Safety of Ridinilazole Compared with Vancomycin for the Treatment of Clostridioides difficile Infection. Open Forum Infectious Diseases. 9(Supplement_2). 6 indexed citations
3.
4.
Tempero, Margaret A., Do‐Youn Oh, Teresa Macarulla, et al.. (2019). Ibrutinib in combination with nab-paclitaxel and gemcitabine as first-line treatment for patients with metastatic pancreatic adenocarcinoma: results from the phase 3 RESOLVE study. Annals of Oncology. 30. iv126–iv126. 16 indexed citations
5.
Jones, Jeffrey A., Anthony R. Mato, Steven Coutré, et al.. (2018). Evaluation of 230 patients with relapsed/refractory deletion 17p chronic lymphocytic leukaemia treated with ibrutinib from 3 clinical trials. British Journal of Haematology. 182(4). 504–512. 32 indexed citations
6.
O’Brien, Susan, Peter Hillmen, Steven Coutré, et al.. (2018). Safety Analysis of Four Randomized Controlled Studies of Ibrutinib in Patients With Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma or Mantle Cell Lymphoma. Clinical Lymphoma Myeloma & Leukemia. 18(10). 648–657.e15. 63 indexed citations
7.
Moreno, Carol, Richard Greil, Fatih Demırkan, et al.. (2018). Ibrutinib plus obinutuzumab versus chlorambucil plus obinutuzumab in first-line treatment of chronic lymphocytic leukaemia (iLLUMINATE): a multicentre, randomised, open-label, phase 3 trial. The Lancet Oncology. 20(1). 43–56. 380 indexed citations breakdown →
8.
Coutré, Steven, Richard R. Furman, Ian W. Flinn, et al.. (2017). Extended Treatment with Single-Agent Ibrutinib at the 420 mg Dose Leads to Durable Responses in Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma. Clinical Cancer Research. 23(5). 1149–1155. 47 indexed citations
9.
Tempero, Margaret A., Lisa M. Coussens, Lawrence Fong, et al.. (2016). A randomized, double-blind, placebo-controlled study of ibrutinib, a Bruton tyrosine kinase inhibitor, with nab-paclitaxel and gemcitabine in the first-line treatment of patients with metastatic pancreatic adenocarcinoma (RESOLVE).. Journal of Clinical Oncology. 34(15_suppl). TPS2601–TPS2601. 8 indexed citations
10.
Miklos, David B., Corey Cutler, Mukta Arora, et al.. (2016). Multicenter Open-Label Phase 2 Study of Ibrutinib in Chronic Graft Versus Host Disease (cGVHD) after Failure of Corticosteroids. Blood. 128(22). LBA–3. 14 indexed citations
11.
O’Brien, Susan, Richard R. Furman, Steven Coutré, et al.. (2016). Five-Year Experience with Single-Agent Ibrutinib in Patients with Previously Untreated and Relapsed/Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Leukemia. Blood. 128(22). 233–233. 65 indexed citations
12.
O’Brien, Susan, Steven Coutré, Richard R. Furman, et al.. (2015). Durable Responses Including Complete Responses in CLL Following Long Term Treatment With Single-agent Ibrutinib 420 mg. Clinical Lymphoma Myeloma & Leukemia. 15. S23–S23. 1 indexed citations
13.
Barr, Paul M., Jennifer R. Brown, Peter Hillmen, et al.. (2015). Dose adherence and baseline exposure analysis of the ibrutinib 420 mg dose administered to patients with previously treated chronic lymphocytic leukemia (CLL).. Journal of Clinical Oncology. 33(15_suppl). 7012–7012. 6 indexed citations
14.
Wodarz, Dominik, Naveen Garg, Natalia L. Komarova, et al.. (2014). Kinetics of CLL cells in tissues and blood during therapy with the BTK inhibitor ibrutinib. Blood. 123(26). 4132–4135. 78 indexed citations
15.
Jones, Jeffrey A., Peter Hillmen, Steven Coutré, et al.. (2014). Pattern of Use of Anticoagulation and/or Antiplatelet Agents in Patients with Chronic Lymphocytic Leukemia (CLL) Treated with Single-Agent Ibrutinib Therapy. Blood. 124(21). 1990–1990. 13 indexed citations
16.
Byrd, John C., Jennifer R. Brown, Susan O’Brien, et al.. (2014). Randomized comparison of ibrutinib versus ofatumumab in relapsed or refractory (R/R) chronic lymphocytic leukemia/small lymphocytic lymphoma: Results from the phase III RESONATE trial.. Journal of Clinical Oncology. 32(18_suppl). LBA7008–LBA7008. 7 indexed citations
17.
Chang, Betty, Richard R. Furman, Marc Zapatka, et al.. (2013). Use of tumor genomic profiling to reveal mechanisms of resistance to the BTK inhibitor ibrutinib in chronic lymphocytic leukemia (CLL).. Journal of Clinical Oncology. 31(15_suppl). 7014–7014. 30 indexed citations
18.
Choi, Michael Y., Januario E. Castro, Hongying Li, et al.. (2013). Lenalidomide and Rituximab For The Treatment Of Patients With Relapsed Or Refractory Chronic Lymphocytic Leukemia: Results Of Planned Interim Analysis. Blood. 122(21). 5299–5299. 2 indexed citations
19.
Castro, Januario E., Michael Y. Choi, Hongying Li, et al.. (2013). Ofatumumab in combination with high-dose methylprednisolone for the treatment of patients with relapsed or refractory chronic lymphocytic leukemia.. Journal of Clinical Oncology. 31(15_suppl). 7124–7124. 1 indexed citations
20.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Carolyn Owen Breakdown of academic impact, for papers by Francesca Romana Mauro Breakdown of academic impact, for papers by Preetesh Jain Breakdown of academic impact, for papers by Marı́a Rozman Breakdown of academic impact, for papers by Jacqueline C. Barrientos Breakdown of academic impact, for papers by Jeffrey Matous Breakdown of academic impact, for papers by Leslie A. Andritsos Breakdown of academic impact, for papers by Wei Ding Breakdown of academic impact, for papers by E Montserrat Breakdown of academic impact, for papers by KR Rai
Rankless by CCL
2026